Cancer Research and Treatment

Cancer Research and Treatment Search

> Browse Articles > Search

Lung and Thoracic cancer

miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37

Mi Seong Kim, So Hui Kim, Sei Hoon Yang, Min Seuk Kim

Cancer Res Treat. 2022;54(2):445-457. Published online August 3, 2021 DOI: https://doi.org/10.4143/crt.2021.622

Cited By 3

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy

Ji Young Choi, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Seong Jin Jo

Cancer Res Treat. 2019;51(1):169-177. Published online April 5, 2018 DOI: https://doi.org/10.4143/crt.2017.491

Cited By 3

Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial

Jin Hyoung Kang, Myung-Ju Ahn, Dong-Wan Kim, Eun Kyung Cho, Joo-Hang Kim, Sang Won Shin, Xin Wang, Jong Seok Kim, Mauro Orlando, Keunchil Park

Cancer Res Treat. 2016;48(2):458-464. Published online October 14, 2015 DOI: https://doi.org/10.4143/crt.2015.135

Cited By 1

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients

Seung-Hoon Beom, Dong-Wan Kim, Sung Hoon Sim, Bhumsuk Keam, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Dae Seog Heo

Cancer Res Treat. 2016;48(1):88-97. Published online March 3, 2015 DOI: https://doi.org/10.4143/crt.2014.201

Cited By 10

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer

Young Saing Kim, Eun Kyung Cho, Hyun Sun Woo, Junshik Hong, Hee Kyung Ahn, Inkeun Park, Sun Jin Sym, Sun Young Kyung, Shin Myung Kang, Jeong-Woong Park, Sung Hwan Jeong, Jinny Park, Jae Hoon Lee, Dong Bok Shin

Cancer Res Treat. 2016;48(1):80-87. Published online March 2, 2015 DOI: https://doi.org/10.4143/crt.2014.307

Cited By 8

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution

Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo

Cancer Res Treat. 2013;45(3):178-185. Published online September 30, 2013 DOI: https://doi.org/10.4143/crt.2013.45.3.178

Cited By 9

Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman

Hoon-Kyo Kim, Myeong Im Ahn, Jinyoung Yoo, Chi Hong Kim, Hong-Jun Yang, Byoung Yong Shim

Cancer Res Treat. 2007;39(1):37-39. Published online March 31, 2007 DOI: https://doi.org/10.4143/crt.2007.39.1.37

Cited By 2

Gefitinib Trial in a Fanconi's Anemia Patient with Multiple Squamous Cell Carcinomas and Hepatocellular Carcinoma

Hae Sun Jung, Gun-Woo Byun, Kyoung-Eun Lee, Yeung Chul Mun, Seung Hyun Nam, Jung Mi Kwon, Shi Nae Lee, Seock-Ah Im, Chu-Myong Seong, Soon Nam Lee

Cancer Res Treat. 2005;37(6):370-373. Published online December 31, 2005 DOI: https://doi.org/10.4143/crt.2005.37.6.370

Cited By 4

Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410 FAX: +82-2-792-1410 E-mail: journal@cancer.or.kr

About | Browse Articles | Current Issue | For Authors and Reviewers